Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The PERSEPHONE trial: 6 months and 12 months of trastuzumab in breast cancer

Best of ASCO® 2018 Miami Symposium

13 - 14 Jul 2018

Published: 7 Aug 2018

Views: 2287

Rating:

Save

Prof Mariana Chavez-McGregor - University of Texas MD Anderson Cancer Center, Houston, USA

Prof Chavez-McGregor speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about the PERSEPHONE trial.

PERSEPHONE studies whether women with early breast cancer can safely have trastuzumab for 6 months instead of 12.

Prof Chavez-McGregor describes how the results are generally positive, but also touches upon the drawbacks of the study.

Related Videos

Grand Rounds: Improving quality of patient-centred care

Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado

Grand Rounds: Improving quality of patient-centred care ( Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado )

Supporting breast cancer patients in Vietnam

Ms Thu Ha Hoang - Founder, Kien Cuong Cancer Support Club, Vietnam

Supporting breast cancer patients in Vietnam ( Ms Thu Ha Hoang - Founder, Kien Cuong Cancer Support Club, Vietnam )

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of...

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

Assessment of QoL results and correlation with survival outcomes in phase III...

Dr Alberto Servetto - University of Naples Federico II, Naples, Italy

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC ( Dr Alberto Servetto - University of Naples Federico II, Naples, Italy )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Single-dose IORT during lumpectomy for breast cancer an innovative patient...

Dr Jayant Vaidya - University College London, London, UK

Single-dose IORT during lumpectomy for breast cancer an innovative patient-centred treatment ( Dr Jayant Vaidya - University College London, London, UK )

Global adoption of single-shot targeted IORT for breast cancer

Dr Jayant Vaidya - University College London, London, UK

Global adoption of single-shot targeted IORT for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation...

Dr Jayant Vaidya - University College London, London, UK

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )

The advancements in radiotherapy for breast cancer patients

Prof Ahlam Dohal - King Fahd Specialised Hospital Dammam, Dammam, Saudi Arabia

The advancements in radiotherapy for breast cancer patients ( Prof Ahlam Dohal - King Fahd Specialised Hospital Dammam, Dammam, Saudi Arabia )

More from ecancer